Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Oncogenex Pharmaceuticals
Evaluate
September 29, 2016
Esmo preview – Novel checkpoints add to the Parp showdown
March 17, 2016
Revisiting a predictor of failure in the post-Celator world
January 21, 2016
Oncogenex finds itself in biotech no-man’s land
June 03, 2015
Asco Event Analyzer – 2015’s winners and losers
April 22, 2015
Growth of anti-PD1 therapy threatens traditional second line chemo in NSCLC
December 31, 2014
Pharma regulatory and development news over Christmas 2014
December 24, 2014
Cyclacel and Neovacs enter the graveyard shift
July 03, 2014
Market wobble fails to derail mid and small-caps
June 27, 2014
Upcoming events: Roche’s cobimetinib in melanoma and Oncogenex’s apatorsen
June 04, 2012
Asco - Metastatic prostate cancer space increasingly a battleground
January 07, 2010
Clinical surprises drive small cap risers
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics
